Navigation Links
The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe
Date:7/13/2014

Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology.

"The good news is that 5-year survival for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in the early 2000s such as rituximab for non-Hodgkin lymphoma and imatinib for chronic myeloid leukaemia", explains study leader Dr Milena Sant from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.*

"But there continue to be persistent differences between regions. For example, the uptake and use of new technologies and effective treatments has been far slower in eastern Europe than other regions. This might have contributed to the large differences in the management and outcomes of patients."*

The EUROCARE study analysed data from 30 cancer registries** covering all patients diagnosed in 20 European countries to compare changes in 5-year survival for more than 560 400 adults (aged 15 years and older) diagnosed with 11 lymphoid and myeloid cancers between 1997 and 2008, and followed up to the end of 2008.

Some blood cancers have shown particularly large increases in survival between 1997 and 2008eg, follicular lymphoma (59% to 74%), diffuse large B-cell lymphoma (42% to 55%), chronic myeloid leukaemia (32% to 54%), and acute promyelocytic leukaemia (50% to 62%).

The greatest improvements in survival during 1997� have been in northern, central, and eastern Europe, even though adults in eastern Europe (where survival in 1997 was the lowest) continue to have lower survival for most blood cancers than elsewhere.

But survival gains have been lower in southern Europe and the UK. For example, improvements in 5-year
'/>"/>

Contact: Dr. Milena Sant
milena.sant@istitutotumori.mi.it
39-022-390-3519
The Lancet
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Premier global health journal, The Lancet, releases series on universal health coverage
2. Indias patent laws under pressure: The Lancet special report
3. Lancet Oncology: Long-term side-effects of targeted therapies in pediatric cancer patients
4. 1-year results of ADAPT-DES trial published in The Lancet
5. More Babies are Oversized as Maternal Obesity Rate Rises, Lancet Report Says
6. The Lancet: China halves tuberculosis prevalence in just 20 years
7. The Lancet journals: World TB Day media alert
8. The Lancet Diabetes & Endocrinology: Large clinical trials to evaluate risks of testosterone treatment urgently needed
9. The Lancet: UK has one of the highest death rates for children in western Europe
10. E-cigarettes far less harmful than cigarettes, says Lancet researcher at INFORMS Conference
11. The Lancet: Midwifery matters more than ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Developers of FCPX 3rd Party Products have announced ... Plugin from Pixel Film Studios. , “ProWorld has pushed the ... users now have the ability to create a 3D world ... Pixel Film Studios. “Blurring the line between professional and armature, ... turn a 2D HDRI image or Skybox Texture into a ...
(Date:9/1/2014)... 2014 Psychogenic Non-epileptic Seizures (PNES), also ... disorder that can have devastating effects on those who ... seizures however, they are not produced by electrical anomalies ... It is estimated that the numbers of persons suffering ... sclerosis. , Dr. Lorna Myers, Director of ...
(Date:8/31/2014)... An analysis of 32 studies compiled by ... link between lower levels of Vitamin D and a ... August 2014 issue of American Journal of Public ... Vitamin D found in blood. , Researchers found ... than 9 nanograms/milliliter (ng/mL) were twice as likely to ...
(Date:8/31/2014)... 2014 MedixSafe has become very popular ... and narcotics lockers . Electronic Security Specialists ... for distribution worldwide. “We have now shipped multiple orders ... MedixSafe Sales Manager , MedixSafe is a division of ... network cabling company with over 30 years in the ...
(Date:8/31/2014)... 2014 Just in time for Washington’s Indian ... wild, sustainable Alaska Salmon, award winning chowder and ... Duke's Green Lake location , Sunday, September 28, 2014 from ... several ethnic salmon BBQ culinary delights. Live music will add ... Hawaii, Puerto Rico and Mexico will be featured. “There ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... took place even in prehistoric times. , , FRIDAY, June 13 ... based on the findings of a prehistoric mass grave in ... evidence from 34 skeletons dating back to around 5000 B.C. ... over the need for female companionship. , While adult ...
... June 13 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases,announced ... Chief Executive Officer,will present a Company overview ... Organization 2008 Annual International Convention,being held June ...
... trachomatis, the most ... Calif., June 13 Roche announced today that,its new ... Mark,certification, allowing it to be sold for clinical use ... target approach to help ensure,reliability of test results even ...
... terrorist attacks of September 11, 2001, had lasting psychological ... World Trade Center Health Registry, show that one in ... (PTSD) two to three years after the attacks. The ... three times the usual rate in the years following ...
... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... Today a minority of,the U.S. Senate blocked critical ... million Americans who depend on it. The Medicare,Improvements ... improved,Medicare,s prevention, mental health, and low-income programs and,instituted ...
... Synovics,Pharmaceuticals, Inc., (OTC Bulletin Board: SYVC) a ... 2008, it formalized,a strategic partnership with Maneesh Pharmaceuticals, ... ("JV"). The JV between the,companies is intended to ... have access,to assets of Maneesh including personnel, drug ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
Binocular indirect ophthalmic lenses. Median field diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series ... lenses. General retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Standard BIO examinations....
Medicine Products: